Olema Pharmaceuticals Files 8-K
Ticker: OLMA · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1750284
| Field | Detail |
|---|---|
| Company | Olema Pharmaceuticals, INC. (OLMA) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $19.00, $190.0 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, sec-filing
TL;DR
Olema Pharma filed a standard 8-K on Nov 19, 2025. No major news.
AI Summary
Olema Pharmaceuticals, Inc. filed an 8-K on November 19, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about new events, financial figures, or material agreements, but rather serves as a standard disclosure.
Why It Matters
This 8-K filing indicates a routine update or disclosure from Olema Pharmaceuticals, Inc. to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K and does not disclose any new material events, risks, or financial changes.
Key Players & Entities
- Olema Pharmaceuticals, Inc. (company) — Registrant
- November 19, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 780 Brannan Street, San Francisco, California 94103 (address) — Principal Executive Offices
- 415 - 651-3316 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Olema Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of November 19, 2025.
On what date was this 8-K filing reported?
The 8-K filing was reported on November 19, 2025.
In which state is Olema Pharmaceuticals, Inc. incorporated?
Olema Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Olema Pharmaceuticals, Inc.?
The principal executive office address is 780 Brannan Street, San Francisco, California 94103.
Does this filing disclose any specific new material events or financial results?
No, this filing is a standard 8-K and does not appear to disclose specific new material events or detailed financial results beyond the categorization of items reported.
Filing Stats: 1,011 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2025-11-19 17:20:43
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share OLMA The Nasdaq Global Se
- $19.00 — on Stock"), at a price to the public of $19.00 per share of Common Stock. The closing
- $190.0 m — from the offering will be approximately $190.0 million, before deducting underwriting di
Filing Documents
- d46182d8k.htm (8-K) — 30KB
- d46182dex11.htm (EX-1.1) — 197KB
- d46182dex51.htm (EX-5.1) — 8KB
- g46182dsp05.jpg (GRAPHIC) — 6KB
- 0001193125-25-288343.txt ( ) — 409KB
- olma-20251119.xsd (EX-101.SCH) — 3KB
- olma-20251119_lab.xml (EX-101.LAB) — 17KB
- olma-20251119_pre.xml (EX-101.PRE) — 11KB
- d46182d8k_htm.xml (XML) — 3KB
Forward Looking Statements
Forward Looking Statements Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement by and between the Company and TD Securities (USA) LLC, as representative of the several underwriters named therein, dated November 18, 2025. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Olema Pharmaceuticals, Inc. Date: November 19, 2025 By: /s/ Shane Kovacs Shane Kovacs Chief Operating and Financial Officer